Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms
Completed · Phase 1
Conditions studied: Postmenopause
In brief
The purpose of the study is to understand how bazedoxifene is absorbed in the body when it is given in combination with 2 different formulations of conjugated estrogens. It is an open label study with no placebo control or comparator drugs. Subjects will take one dose of the investigation formulation daily for 14 days.
Key facts
- Study ID
- NCT00479778
- Run by
- Wyeth is now a wholly owned subsidiary of Pfizer
- People needed
- 72
- Starts
- 2007-04-01
- Expected to finish
- 2007-07-01
- Last updated by the study team
- 2007-12-28
Who can join
Age: 40 and older, up to 65. Sex: female. Healthy volunteers: accepted.
Where it is running
- Study site — Gainesville, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.